TUESDAY, April 9, 2024 (HealthDay News) — Semaglutide reduces heart failure-related symptoms in patients with obesity-related heart failure and type 2 diabetes with preserved ejection fraction, according to a study published online April 6. It is said to lead to a significant reduction in symptoms and physical limitations.inside New England Medical Journal The event will be held in conjunction with the American College of Cardiology’s annual meeting in Atlanta, April 6-8.

Mikhail N. Kosiborod, MD, of St. Luke’s Mid-America Heart Institute in Kansas City, Missouri, and his colleagues randomly assigned 616 patients with preserved heart failure and an ejection fraction (BMI) of 30 kg/m3.² Patients with type 2 diabetes should receive semaglutide or a placebo once a week for 52 weeks. Change from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and change in body weight were the primary endpoints.

The researchers found that the mean change in KCCQ-CSS was 13.7 points and 6.4 points for semaglutide and placebo, respectively, and the corresponding mean percent change in body weight was -9.8 percent and -3.4 percent. For confirmatory secondary endpoints such as estimated between-group difference in change in 6-minute walk distance and estimated treatment rate in change in C-reactive protein levels, results favored semaglutide over placebo. Serious adverse events were reported in 17.7% and 28.8% of the semaglutide and placebo groups, respectively.

“Once-weekly semaglutide, 2.4 mg, significantly reduced heart failure-related symptoms and physical limitations and was associated with greater weight loss than placebo at 52 weeks,” the authors wrote. .

Several authors disclosed relationships with biopharmaceutical companies, including Novo Nordisk, which manufactured semaglutide and funded the research.

Summary/Full text (subscription or payment may be required)

For more information

Copyright © 2024 HealthDay. All rights reserved.